Products under development

Indication	Dosage form	Market potential (annual sales)	Strengths	Progress
Sialorrhoea	Oral syrup	1 billion USD	New patentable combination with unique drug actions	Phase II
Tuberculosis	Capsule	－	New drug with lower side effects (liver toxicity)	Phase III
Attention Deficit Hyperactivity Disorder	Capsule	1.3 billion USD	Enhance drug efficacy and improve patients’ drug adherence	NDA